<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237909</url>
  </required_header>
  <id_info>
    <org_study_id>ATADEK 2019/8-18</org_study_id>
    <nct_id>NCT04237909</nct_id>
  </id_info>
  <brief_title>Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency</brief_title>
  <official_title>Effects of Intraovarian Injection of Autologous Platelet Rich Plasma on Ovarian Reserve and IVF Outcome Parameters in Women With Premature Ovarian Insufficiency and Poor Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reproductive age women diagnosed with poor ovarian response (POR) based on Poseidon criteria
      and premature ovarian insufficiency (POI) based on ESHRE criteria and with a history of at
      least one prior failed IVF cycle will be recruited for the study. Antral follicle count
      (AFC), serum anti-mullerian hormone (AMH), and early follicular phase serum follicle
      stimulating hormone (FSH) levels will determined at baseline. Autologous blood obtained from
      peripheral vein will be used to prepare PRP following standard protocols and will be injected
      to at least one ovary. Ovarian reserve parameters and IVF outcomes will be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reproductive age women diagnosed with POR based on Poseidon criteria and POI based on
      European Society of Human Reproduction and Endocrinology (ESHRE) criteria with a history of
      at least one prior failed IVF cycle will recruited for the study. Antral follicle count
      (AFC), serum anti-mullerian hormone (AMH), and early follicular phase serum follicle
      stimulating hormone (FSH) levels will be determined at baseline. Autologous blood obtained
      from peripheral vein will be used to prepare PRP following standard protocols. PRP injection
      will be performed under sedation anesthesia, using a 35 cm 17 G needle under transvaginal
      ultrasound guidance. On the 2-4th days of the first six menstrual cycles following the
      procedure, AFC, AMH, and FSH levels will be re-assessed. Patients with at least one antral
      follicle will be started on ovarian stimulation for in-vitro fertilization- intracytoplasmic
      sperm injection (IVF-ICSI), followed by embryo banking/ preimplantation genetic testing-
      aneuploidy (PGT-A) or embryo transfer. Markers of ovarian reserve (AFC, FSH, AMH), and IVF
      laboratory outcome parameters (number of metaphase II (MII) oocytes, 2PN(pronucleus) embryos,
      cleavage stage, blastocyst embryos) will be followed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>After the couples are recruited for the study, Antral follicle count (AFC), serum anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) levels will be determined at baseline and will be repeated beginning with the first menstrual cycle. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary Ovarian reserve (AFC, FSH, AMH), and IVF laboratory outcome parameters (number of MII oocytes, 2PN embryos, cleavage stage embryos) will be followed for six sequential months. Spontaneous pregnancies will also be recorded.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovarian reserve parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with intraovarian injection of autologous PRP as assessed by blood hormone analysis and ultrasonographic antral follicle counts, change in serum FSH, AMH levels and number of antral follicle counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian response to stimulation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with intraovarian injection of autologous PRP as assessed by number antral follicle counts on ultrasound, eggs, and embryos in the laboratory, change from baseline in number of developing follicles, and percentage of obtained eggs and fertilized embryos.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>IVF outcomes</measure>
    <time_frame>15 months</time_frame>
    <description>Number of participants with ovarian PRP as assessed by number of clinical pregnancies, change in the percentage of clinical pregnancy rates with IVF treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <condition>Diminished Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Ovarian Reserve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diminished ovarian reserve or premature ovarian insufficiency</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP injection into at least one ovary</intervention_name>
    <description>The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.</description>
    <arm_group_label>Ovarian Reserve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a history of &gt;1 year infertility duration with at least one ovary, who
             fulfilled the ESHRE criteria,

          -  Patients diagnosed with POR based on Poseidon criteria and with a history of at least
             one prior failed IVF cycle

        Exclusion Criteria:

          -  Presence of pregnancy,

          -  previous diagnosis of any malignancy,

          -  ovarian insufficiency secondary to sex chromosome etiology,

          -  prior major lower abdominal surgery resulting in pelvic adhesions,

          -  anticoagulant use for which plasma infusion is contraindicated,

          -  current or previous (Immunoglobulin A (IgA) deficiency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yigit Cakiroglu, Assoc.Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Acibadem University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yigit Cakiroglu, Assoc.Prof.</last_name>
    <phone>+90-532-585 65 88</phone>
    <email>dryigit1@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bulent Tıras, Prof.</last_name>
    <phone>+90-533-290 37 17</phone>
    <email>bulent.tiras@acibadem.com.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Acıbadem University</name>
      <address>
        <city>Istanbul</city>
        <zip>34752</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yigit Cakiroglu, Assoc.Prof.</last_name>
      <phone>+90-532-585 65 88</phone>
      <email>dryigit1@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bulent Tıras, Prof.</last_name>
      <phone>+90-533-290 37 17</phone>
      <email>bulent.tiras@acibadem.com.tr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number), Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26.</citation>
    <PMID>26921622</PMID>
  </reference>
  <reference>
    <citation>European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37. doi: 10.1093/humrep/dew027. Epub 2016 Mar 22.</citation>
    <PMID>27008889</PMID>
  </reference>
  <results_reference>
    <citation>Leijdekkers JA, Eijkemans MJC, van Tilborg TC, Oudshoorn SC, van Golde RJT, Hoek A, Lambalk CB, de Bruin JP, Fleischer K, Mochtar MH, Kuchenbecker WKH, Laven JSE, Mol BWJ, Torrance HL, Broekmans FJM; OPTIMIST study group. Cumulative live birth rates in low-prognosis women. Hum Reprod. 2019 Jun 4;34(6):1030-1041. doi: 10.1093/humrep/dez051.</citation>
    <PMID>31125412</PMID>
  </results_reference>
  <results_reference>
    <citation>Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol. 2018 Sep;34(9):756-760. doi: 10.1080/09513590.2018.1445219. Epub 2018 Feb 28.</citation>
    <PMID>29486615</PMID>
  </results_reference>
  <results_reference>
    <citation>Sfakianoudis K, Simopoulou M, Nitsos N, Lazaros L, Rapani A, Pantou A, Koutsilieris M, Nikas Y, Pantos K. Successful Implantation and Live Birth Following Autologous Platelet-rich Plasma Treatment for a Patient with Recurrent Implantation Failure and Chronic Endometritis. In Vivo. 2019 Mar-Apr;33(2):515-521. doi: 10.21873/invivo.11504.</citation>
    <PMID>30804135</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Acibadem University</investigator_affiliation>
    <investigator_full_name>Bulent Tiras</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

